tiprankstipranks
Advertisement
Advertisement

MAZE Stock Latest News

Maze Therapeutics price target lowered to $64 from $68 at Truist
The FlyMaze Therapeutics price target lowered to $64 from $68 at Truist
2d ago
MAZE
MAZE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
MAZE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
12d ago
MAZE
Maze Therapeutics price target raised to $58 from $52 at JPMorgan
PremiumThe Fly
Maze Therapeutics price target raised to $58 from $52 at JPMorgan
16d ago
MAZE
Encouraging HORIZON Phase 2 Data and Favorable Safety Support Buy Rating on Maze’s APOL1 Inhibitor MZE829
PremiumRatings
Encouraging HORIZON Phase 2 Data and Favorable Safety Support Buy Rating on Maze’s APOL1 Inhibitor MZE829
21d ago
MAZE
Midday Fly By: Merck to acquire Terns, Arm CPU launch applauded
PremiumThe Fly
Midday Fly By: Merck to acquire Terns, Arm CPU launch applauded
22d ago
GM
AMD
Maze Therapeutics falls -29.8%
PremiumThe FlyMaze Therapeutics falls -29.8%
22d ago
MAZE
Maze Therapeutics share sell-off an ‘overreaction,’ says Raymond James
Premium
The Fly
Maze Therapeutics share sell-off an ‘overreaction,’ says Raymond James
22d ago
MAZE
VRTX
Maze Therapeutics falls -33.2%
Premium
The Fly
Maze Therapeutics falls -33.2%
22d ago
MAZE
Leerink remains bullish on Maze, says Vertex comparison ‘apples to oranges’
PremiumThe Fly
Leerink remains bullish on Maze, says Vertex comparison ‘apples to oranges’
22d ago
MAZE
VRTX
Maze Therapeutics price target raised to $110 from $60 at H.C. Wainwright
PremiumThe Fly
Maze Therapeutics price target raised to $110 from $60 at H.C. Wainwright
22d ago
MAZE
Maze Therapeutics reports Q4 EPS (65c), consensus (78c)
PremiumThe Fly
Maze Therapeutics reports Q4 EPS (65c), consensus (78c)
22d ago
MAZE
Maze Therapeutics up 15% at $56.43 after Q4 results and MZE829 trial data
PremiumThe Fly
Maze Therapeutics up 15% at $56.43 after Q4 results and MZE829 trial data
22d ago
MAZE
Maze Therapeutics announces positive topline data from Phase 2 HORIZON Trial
PremiumThe FlyMaze Therapeutics announces positive topline data from Phase 2 HORIZON Trial
22d ago
MAZE
Maze Therapeutics adds Neil Kumar to board leadership
Premium
Company Announcements
Maze Therapeutics adds Neil Kumar to board leadership
22d ago
8K
MAZE
Block upgraded, Starbucks downgraded: Wall Street’s top analyst calls
Premium
The Fly
Block upgraded, Starbucks downgraded: Wall Street’s top analyst calls
29d ago
CF
EXR
Maze Therapeutics initiated with a Buy at Truist
PremiumThe Fly
Maze Therapeutics initiated with a Buy at Truist
30d ago
MAZE
Maze Therapeutics price target raised to $58 from $43 at Wedbush
PremiumThe Fly
Maze Therapeutics price target raised to $58 from $43 at Wedbush
1M ago
MAZE
Qualcomm downgraded, Rivian upgraded: Wall Street’s top analyst calls
PremiumThe Fly
Qualcomm downgraded, Rivian upgraded: Wall Street’s top analyst calls
1M ago
LTH
NVO
Maze Therapeutics initiated with an Outperform at Mizuho
PremiumThe Fly
Maze Therapeutics initiated with an Outperform at Mizuho
1M ago
MAZE
Underappreciated Cardiometabolic Upside: Validating Maze’s SLC6A19 Inhibitor MZE782 and Supporting a Buy on MAZE
PremiumRatingsUnderappreciated Cardiometabolic Upside: Validating Maze’s SLC6A19 Inhibitor MZE782 and Supporting a Buy on MAZE
1M ago
MAZE
Buy Rating on Maze Therapeutics: Favorable HORIZON Phase 2 Setup, Validated APOL1 Biology, and Underappreciated Pipeline Upside
Premium
Ratings
Buy Rating on Maze Therapeutics: Favorable HORIZON Phase 2 Setup, Validated APOL1 Biology, and Underappreciated Pipeline Upside
1M ago
MAZE
Maze Therapeutics price target raised to $58 from $46 at Guggenheim
Premium
The Fly
Maze Therapeutics price target raised to $58 from $46 at Guggenheim
1M ago
MAZE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >